Literature DB >> 22226414

Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state.

Bradley S Quon1, Donald L Patrick, Todd C Edwards, Moira L Aitken, Ronald L Gibson, Alan Genatossio, Sharon McNamara, Christopher H Goss.   

Abstract

BACKGROUND: Evaluation of physical activity is integral to the assessment of daily physical function and a potential objective outcome measure for clinical trials. We evaluated the feasibility of using pedometers to measure physical activity in adolescents and adults with cystic fibrosis (CF) and assessed the responsiveness of its measurement to changes in health state.
METHODS: Participants were recruited through two CF clinics in Seattle, WA. Subjects were instructed to use their pedometer for at least one ill and two well periods (each lasting 7 days). Step rate was calculated as steps per hour of use. Daily symptoms were also recorded using the CF Respiratory Symptom Diary (CFRSD). Generalized estimating equation linear regression was used to compare mean step rate between health states and by self-reported symptom category.
RESULTS: We enrolled 30 CF patients with a mean (±SD) age of 22 (±7) years and a mean forced expiratory volume in 1s (FEV(1)) of 57% (±25%) predicted. The mean period step rate increased from 397 (95% CI 324-497) steps/hour when ill to 534 (95% CI 413-654) steps/hour when well (p=0.015). Pedometer-recorded step rate also correlated with self-reported physical activity items on the CFRSD.
CONCLUSION: Step rate measured with a pedometer correlates significantly with changes in health status and self-reported activity, and could be used as an outcome measure in CF.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22226414      PMCID: PMC4197911          DOI: 10.1016/j.jcf.2011.12.002

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  31 in total

1.  Commercially available pedometers: considerations for accurate step counting.

Authors:  Edward L Melanson; Joan R Knoll; Melanie L Bell; William T Donahoo; J O Hill; Lana J Nysse; Lorraine Lanningham-Foster; John C Peters; James A Levine
Journal:  Prev Med       Date:  2004-08       Impact factor: 4.018

2.  Evaluation of the SenseWear activity monitor during exercise in cystic fibrosis and in health.

Authors:  Tiffany Jane Dwyer; Jennifer Ailsey Alison; Zoe Jane McKeough; Mark Russell Elkins; Peter Thomas Patrick Bye
Journal:  Respir Med       Date:  2009-05-23       Impact factor: 3.415

3.  Comparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosis.

Authors:  Antonia V Bennett; Donald L Patrick; James F Lymp; Todd C Edwards; Christopher H Goss
Journal:  J Cyst Fibros       Date:  2010-12       Impact factor: 5.482

4.  Habitual physical activity in children and adolescents with cystic fibrosis.

Authors:  P A Nixon; D M Orenstein; S F Kelsey
Journal:  Med Sci Sports Exerc       Date:  2001-01       Impact factor: 5.411

5.  Bone health, daily physical activity, and exercise tolerance in patients with cystic fibrosis.

Authors:  Sergio Tejero García; Miguel A Giráldez Sánchez; Pilar Cejudo; Esther Quintana Gallego; Javier Dapena; Rosario García Jiménez; Pedro Cano Luis; Ignacio Gómez de Terreros
Journal:  Chest       Date:  2011-02-03       Impact factor: 9.410

6.  Muscle function and resting energy expenditure in female athletes with cystic fibrosis.

Authors:  Hiran C Selvadurai; Jane Allen; Toos Sachinwalla; James Macauley; Cameron J Blimkie; Peter P Van Asperen
Journal:  Am J Respir Crit Care Med       Date:  2003-09-18       Impact factor: 21.405

7.  Physical activity assessment using a pedometer and its comparison with a questionnaire in a large population survey.

Authors:  M M Sequeira; M Rickenbach; V Wietlisbach; B Tullen; Y Schutz
Journal:  Am J Epidemiol       Date:  1995-11-01       Impact factor: 4.897

8.  Patient-reported respiratory symptoms in cystic fibrosis.

Authors:  C H Goss; T C Edwards; B W Ramsey; M L Aitken; D L Patrick
Journal:  J Cyst Fibros       Date:  2009-05-29       Impact factor: 5.482

9.  Reliability and validity of the habitual activity estimation scale (HAES) in patients with cystic fibrosis.

Authors:  Greg D Wells; Donna L Wilkes; Jane Schneiderman-Walker; Maryam Elmi; Elizabeth Tullis; Larry C Lands; Felix Ratjen; Allan L Coates
Journal:  Pediatr Pulmonol       Date:  2008-04

10.  Reliability of pedometer data in samples of youth and older women.

Authors:  Lisa A Strycker; Susan C Duncan; Nigel R Chaumeton; Terry E Duncan; Deborah J Toobert
Journal:  Int J Behav Nutr Phys Act       Date:  2007-02-17       Impact factor: 6.457

View more
  4 in total

1.  Response.

Authors:  Steven D Nathan; A Whitney Brown; Nargues A Weir
Journal:  Chest       Date:  2014-06       Impact factor: 9.410

2.  Initial development and pilot testing of observer-reported outcomes (ObsROs) for children with cystic fibrosis ages 0-11years.

Authors:  T C Edwards; J Emerson; A Genatossio; S McNamara; C Goss; D L Patrick; F Onchiri; M Rosenfeld
Journal:  J Cyst Fibros       Date:  2018-02-01       Impact factor: 5.482

3.  Higher mobility scores in patients with cystic fibrosis are associated with better lung function.

Authors:  Aneesha Thobani; Jessica A Alvarez; Shaina Blair; Kaila Jackson; Eric R Gottlieb; Seth Walker; Vin Tangpricha
Journal:  Pulm Med       Date:  2015-02-18

4.  Effects of a Long-Term Wearable Activity Tracker-Based Exercise Intervention on Cardiac Morphology and Function of Patients with Cystic Fibrosis.

Authors:  Maria Anifanti; Stavros Giannakoulakos; Elpis Hatziagorou; Asterios Kampouras; John Tsanakas; Asterios Deligiannis; Evangelia Kouidi
Journal:  Sensors (Basel)       Date:  2022-06-28       Impact factor: 3.847

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.